WO2000023463A2 - Fluorescent dye binding peptides - Google Patents
Fluorescent dye binding peptides Download PDFInfo
- Publication number
- WO2000023463A2 WO2000023463A2 PCT/US1999/024266 US9924266W WO0023463A2 WO 2000023463 A2 WO2000023463 A2 WO 2000023463A2 US 9924266 W US9924266 W US 9924266W WO 0023463 A2 WO0023463 A2 WO 0023463A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- peptide
- fluorette
- dye
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6827—Total protein determination, e.g. albumin in urine
- G01N33/6839—Total protein determination, e.g. albumin in urine involving dyes, e.g. Coomassie blue, bromcresol green
Definitions
- the invention relates to peptides that bind to fluorescent dyes, termed "fluorettes", and to methods of making and using the fluorettes.
- the fluorettes can be used in detection and assay systems in vitro and in vivo.
- Fluorophore dyes due to their extraordinar sensitivity and ease of use, are widely used in numerous approaches in fluorescent microscopy, flow cytometry and other detection systems (Haugland. Handbook of fluorescent probes and research chemicals (sixth edition). Molecular Probes, Inc., Eugene OR (1996) and ref. therein).
- ligands or naturally-derived antibodies conjugated directly or indirectly to fluorophores as probes of the expression levels of nearly any given surface-expressed protein on living cells.
- permeable ligands for individual target proteins. In these cases the ligand is either self-fluorescent, becomes fluorescent upon binding or is conjugated to fluorescent adducts.
- reporter enzymes such as ⁇ -galactosidase, ⁇ -glucuronidase, and ⁇ -glucosidase
- reporter enzymes such as ⁇ -galactosidase, ⁇ -glucuronidase, and ⁇ -glucosidase
- fluorogenic dye acted upon by the reporter enzyme(s)
- Lorincz et al. Cytometry 24:321-329 (1996); Krasnow ef al. Science. 251 :81-85 (1991).
- Other systems including ⁇ -lactamase (Zlokamik et al.
- the invention provides peptides that bind to fluorophore dyes
- the peptides are made of naturally occu ⁇ ng ammo acids, non-naturally occurring ammo acids, or combinations thereof
- methods are provided for isolating and identifying peptides that bind to fluorophore dyes.
- the method comprises creating and screening peptide libraries that bind to fluorophores
- complexes of fluorettes bound to fluorophore dyes The binding of the fluorophore by the fluorette may alter the excitation and/or the emission spectrum of the fluorophore
- the present invention provides methods for detecting a fluorette by binding a fluorette to a fluorophore dye and detecting the fluorette/fluorophore dye complex
- Fluorophore dye carriers Fluorescein, Oregon Green 514, Rhodamine Red and Texas Red activated derivatives were covalently linked to the polymer carrier Ultralmk Immobilized DADPA via a 12-atom diaminodipropylamine spacer A spacer is shown as a horizontal thick bar Digits with arrows in the chemical structures of all fluorophore dyes, except Oregon Green 514, show that "mixed isomers" of these fluorophore dye activated derivatives were used for a coupling Figure 2. Biopanning with a peptide phage display library against Fluorescein, Oregon Green 514, Rhodamine Red and Texas Red carriers. A Ph.D.
- -12 phage display peptide library (New England Biolabs) is a combinatorial library of 12-mer peptides fused to the amino-terminus of a minor coat pill protein of the bactenophage M13mp19. Bound phage in four biopanning rounds were calculated as a percentage of eluted phage plaque forming unit (plaque forming unit (pfu)) yield vs input phage plaque forming unit (pfu). All experiments were performed in duplicate. Standard deviations did not exceed 19%.
- FIG. 3 Phage-fluorophore dye binding. Fluorophore dye-specific OG403, OG402, RhR401 and TR401 phage were bound to Oregon Green 514, Fluorescein, Rhodamine Red and Texas Red “free” dyes, respectively (see text). The normalized particle amounts of amplified Ph.D. -12 phage display peptide library (nonspecific phage) were bound in solution with the same dyes as controls. Phage-fluorophore dye complexes were precipitated three times by PEG to remove unbound dye and spotted to a nitrocellulose filter. The filter was scanned on the Storm 840 scanner (Molecular Dynamics). The presented data is from a single scan and image enhancements were done simultaneously on the complete set of dye binding results using NIH Image 1.59 software.
- FIG. 4 Biopanning with four biased combinatorial phage display peptide libraries based on degenerated fluorettes against Fluorescein, Oregon Green 514, Rhodamine Red and Texas Red carriers.
- OG402-91CL, OG403-91CL, RhR401-91CL and TR401-91CL biased combinatorial phage display peptide libraries were subjected to a biopanning against Fluorescein, Oregon Green 514, Rhodamine Red and Texas Red carriers, respectively. Bound phage in three biopanning rounds were calculated as described in a legend to Figure 2. All experiments were performed in duplicate. Standard deviations did not exceed 21 %.
- FIG. 5A and 5B Peptide - Texas Red binding. Excitation and emission spectra. Peptides at the noted concentrations were incubated with Texas Red (50nM), or without, in 0.6ml of TBS for 1 hr at room temperature (RT). Samples were scanned on a spectrofluorimeter (SPEX Fluoromax (Jobin Yvon-SPEX Instruments Co.)). Peak excitation or emission positions are shown in the figure using vertical bars. Excitation and excitation/emission peak shifts for PepTR401(10 ⁇ M)/Texas Red and PepTRS311 (10 ⁇ M)/Texas Red complexes, respectively (A), were reproducible in three independent experiments. The results of a single experiment are presented.
- FIG 7A-D Peptide - Texas Red binding.
- Texas Red-specific peptides TR401 linear
- Figure 6B TRP501 (SKVILFE-flanked)
- Figure 6D TRP512 (SKVILFE-flanked)
- Figure 6A nonspecific peptide as a negative control
- the peptide-coated beads were washed and incubated with 0.5 ⁇ M Texas Red in TBS buffer for 1 hour at room temperature followed by several washings of beads in order to remove unbound dye.
- Fluorescent and nonfluorescent control beads were photographed on fluorescent microscope Axiophot (Zeiss) using Rhodamine Red/Texas Red filter with the same time exposure for every sample. All binding experiments were accomplished in duplicate and results of a single experiment are shown.
- the present invention provides novel peptides or "fluorettes” that specifically bind fluorophore dyes.
- the present invention also provides novel compositions comprising multimeric fluorettes and fluorettes fused or linked to other compounds or molecules. Also provided are methods to create and modify fluorettes.
- the present invention further provides methods for the use of fluorettes in detecting biological materials, molecules, or target analytes, intracellular events, and intermolecular and intramolecular interactions.
- the fluorettes also find use in in vitro assays and high throughput screens.
- the methods provided are based on the formation and detection of a fluorette/fluorophore dye complex.
- compositions and methods of the present invention provide a significant improvement over conventional light-emitting techniques.
- Fluorettes due to their small size, are not intrusive to the systems being studied and, therefore, permit detection and analysis of a target moiety or molecule while minimizing target modification
- Current light-emitting detection methods involve the use of enzyme-generated fluorochromes, luciferase-generated light, or reporter systems using engineered, inherently fluorescent proteins such as Aequo ⁇ a victoria green fluorescent protein (GFP)
- GFP green fluorescent protein
- the present invention provides a peptide, sometimes termed a "fluorette” herein, that will bind a fluorescent dye
- peptide or “fluorette” herein is meant at least about 8 covalently attached ammo acids
- the peptide may be made up of naturally occurring ammo acids and peptide bonds, or synthetic peptidomimetic structures
- “ammo acid”, or “peptide residue”, as used herein means both naturally occurring and synthetic am o acids
- homo-phenylalanine, citrullme and noreleucme are considered ammo acids for the purposes of the invention
- Ammo acids also includes imino acid residues such as proline and hydroxyprolme
- the side chains may be in either the (R) or the (S) configuration In the preferred embodiment, the ammo acids are in the (S) or L-configuration If non-naturally occurring side chains are used, non-ammo acid substituents may be used, for example to prevent or retard in vivo degradations
- the peptides can be linear or branched Am o acids includes naturally occurring ammo acids or non-naturally occurring am o acids
- Naturally-occurring ammo acids herein is meant ammo acids that are produced by living organisms Naturally-occurring ammo acids are preferred in in vivo embodiments
- Non-naturally-occurring ammo acids ammo acids not produced by a living organism but that can be chemically synthesized
- Non-naturally-occurring ammo acids include, for example, stereoisomers or enantiomers of the naturally-occurring ammo acids in which the ammo side chains, are in either the (D)((R)) or (S)((L)) configuration, ammo acids in which an amine group is bonded to any other but the alpha-carbon or may have more than one amine group bonded to the alpha-carbon, and ammo acids having functional groups or "R" groups not known to occur in nature
- the length of the peptide or fluorette, i e the number of ammo acids, will vary In general, the number of ammo acids varies from about 8 to about 50, with from about 8 to about 40 being preferred, from about 8 to about 25 being particularly preferred, and from about 8 to about 12 being especially preferred
- peptide includes peptide
- the fluorette can be monomenc or multime ⁇ c That is, a monome ⁇ c fluorette binds a single fluorophore
- a multimeric fluorette is two or more associated monomenc fluorettes
- the association of a multimeric fluorette can be either covalent or non-covalent
- the monomers can be joined directly together, for example as a linear fusion (i e , the carboxy terminus of one is joined to the ammo terminus of the second), or as a branched fusion, wherein the attachment of the second monomer is other than to the backbone of the first
- a chemical cross-linker or inclusion of specific reactive group on a fluorette be used to join fluorette monomers
- the monomers may be non-covalently associated, for example, as is more fully outlined below, dimerization sequences can be used to associate two monomers
- a multimeric fluorette can be homomultimenc, i e , all the monomers are the same, and bind the same fluorophore dye, or heteromultime ⁇ c, having at least two different fluorette monomers and can bind different fluorophores
- the fluorette peptides bind to at least one fluorophore dye
- binding herein generally is meant a non-covalent association or interaction between a fluorette and a fluorescent dye
- the non-covalent interactions between the fluorette and dye may involve various types of electrostatic, hydrophilic, and hydrophobic interactions
- Binding may also involve forming one or more covalent bonds between the fluorette and the dye
- Covalent bonds can be formed directly between the fluorette and the dye or can be formed by a cross linker or by inclusion of a specific reactive group on either the fluorette or dye or both molecules
- Binding may also involve a combination of covalent and non-covalent interactions
- the binding is specific
- specific binding herein is meant that the fluorophores will preferentially bind to a fluorophore dye with a binding constant in the range of at least about 10 "6 M 1 to about 10 10 M 1 , with a preferred range being from at least about 10 "6 M 1 to about 10 7 M 1 , with an especially preferred range of from at least about 10 7 M 1 to about 10 10 M
- the fluorettes do not specifically bind to other fluorophore dyes or compounds or moieties, that is, a fluorette is specific to one fluorophore
- a fluorette may bind two or more fluorescent dyes (bind together 2 or more fluorophores or more or capable of binding independently two or more fluorophores); that is, a fluorette may specifically bind another compound or moiety, including another fluorophore, if these molecules have a common structural feature(s) that specifically interact with the fluorette.
- a fluorette may bind two or more fluorescent dyes (bind together 2 or
- a dye is non-fluorescent but becomes fluorescent when bound by a fluorette.
- fluorette binding to a non-fluorescent dye causes the release of a fluorescent moiety. When the fluorescent moiety is released, the fluorette may bind to the released fluorescent moiety, may bind to the non-fluorescent dye, or may be released and therefore free to bind a second molecule of the non-fluorescent dye and repeat this process.
- fluorescent dye or “fluorophore” or “fluorophore dye” herein is meant a compound that absorbs an incident light of a characteristic range of wavelengths or excitation spectrum and dissipates the absorbed energy by emitting light of a characteristic range of wavelengths or emission spectrum.
- excitation spectrum herein is meant the wavelength of incident light absorbed by the fluorophore dye that causes the fluorophore dye to fluoresce.
- emission spectrum herein is meant the characteristic wavelengths of the emitted or fluorescent light produced as the energy of the absorbed incident light is released.
- the excitation and emission spectra for a fluorophore dye may or may not overlap.
- the incident light is in the ultraviolet spectrum and the emitted light is in the visible spectrum.
- Preferred fluorophores include, but are not limited to, Texas Red, Rhodamine Red, Oregon Green 514, and Fluorescein. Examples of fluorescent dyes are found in the Molecular Probes Catalog, 6th Ed., Richard Haugland, Ed., which is expressly incorporated by reference in its entirety.
- the fluorette can further comprise additional components, such as a fusion partner or functional group.
- fusion partner or “functional group” herein is meant a sequence that is associated with the fluorettes, that confers upon the fluorette a function or ability. Fusion partners can be heterologous (i.e. not native to a host cell), or synthetic (not native to any cell).
- Suitable fusion partners include, but are not limited to: a) presentation structures, as defined below, which provide the fluorettes in a conformationally restricted or stable form; b) targeting sequences, defined below, which allow the localization of the flourette into a subcellular or extracellular compartment; c) rescue sequences as defined below, which allows the purification or isolation of the fluorette; d) stability sequences, which confer stability or protection from degradation to the fluorette, for example resistance to proteolytic degradation; e) dimerization sequences, to allow for fluorette dimerization or multimerization; or f) any combination of a), b), c), d), and e), as well as linker sequences as needed.
- the fusion partner is a presentation structure.
- presentation structure or grammatical equivalents herein is meant a sequence, which, when fused to the fluorette, causes the fluorette to assume a conformationally restricted form. Proteins interact with other proteins and molecules largely through conformationally constrained domains. Although small peptides with freely rotating amino- and carboxy-termini can have potent functions as is known in the art, the conversion of such peptide structures into active agents can be difficult due to the inability to predict side-chain positions for peptidomimetic synthesis. Therefore the presentation of fluorettes in conformationally constrained structures will likely lead to higher affinity interactions of the fluorette with its target fluorophore dye. This fact has been recognized in the combinatorial library generation systems using biologically generated short peptides in bacterial phage systems. A number of workers have constructed small domain molecules in which one might present biased-combinatorial libraries of peptide structures.
- presentation structures are preferably peptides or proteins.
- synthetic presentation structures i.e. artificial polypeptides, are capable of presenting fluorettes as a conformationally-restricted domain.
- presentation structures comprise a first portion joined to the N-terminal end of the flourette, and a second portion joined to the C-terminal end of the flourette ; that is, the flourette is inserted into the presentation structure, although variations may be made, as outlined below.
- the presentation structures are selected or designed to have minimal biologically activity when expressed in the target cell.
- presentation structures maximize accessibility to the flourette by presenting it on an exterior loop.
- suitable presentation structures include, but are not limited to, minibody structures, loops on beta-sheet turns and coiled-coil stem structures in which residues not critical to structure are randomized, zinc-finger domains, cysteine-linked (disulfide) structures, transglutaminase linked structures, cyclic peptides, B-loop structures, helical barrels or bundles, leucine zipper motifs, etc.
- presentation structures include dimerization sequences, as defined below.
- the presentation structure is a coiled-coil structure, allowing the presentation of the flourette on an exterior loop.
- coiled- coil structures allow for between 6 to 20 amino acids.
- a preferred coiled-coil presentation structure is as follows:
- MGCAALESEVSALESEVASLESEVAALX, n LAAVKSKLSAVKSKLASVKSKLAACGPP (SEQ ID NO:49).
- the underlined regions represent a coiled-coil leucine zipper region defined previously (see Martin et al., EMBO J. 13(22):5303-5309 (1994), incorporated by reference).
- the bolded X (n) region represents the loop structure and when appropriately replaced with peptides (i.e. fluorettes , generally depicted herein as (X) n , where X is an amino acid residue and n is an integer of at least 5 or 6) can be of variable length.
- a preferred embodiment generates an Xhol site at the double underlined LE site and a Hindlll site at the double-underlined KL site.
- the presentation structure is a minibody structure.
- a "minibody” is essentially composed of a minimal antibody complementarity region.
- the minibody presentation structure generally provides two randomizing regions that in the folded protein are presented along a single face of the tertiary structure.
- a preferred minibody presentation structure is as follows: MGRNSQATSGFTFSHFYMEWVRGGEYI KASRHKHNKYTTEYSASVKGRYIVSRDTSQSILYLQK KKGPP (SEQ ID NO:50).
- the bold, underline regions are the regions which may be contain fluorette sequences.
- the italicized phenylalanine must be invariant in the first randomizing region.
- the entire peptide is cloned in a three-oligonucleotide variation of the coiled-coil embodiment, thus allowing two different randomizing regions to be incorporated simultaneously.
- This embodiment utilizes non-palindromic BstXI sites on the termini.
- the presentation structure is a sequence that contains generally two cysteine residues, such that a disulfide bond may be formed, resulting in a conformationally constrained sequence.
- This embodiment is particularly preferred when fluorettes are to be secreted from a cell.
- any number of flourettes, with or without spacer or linking sequences may be flanked with cysteine residues.
- effective presentation structures may be generated by the flourettes themselves.
- the flourettes may be "doped" with cysteine residues which, under the appropriate redox conditions, may result in highly crosslinked structured conformations, similar to a presentation structure.
- the flourettes may be controlled to contain a certain number of residues to confer ⁇ -sheet or ⁇ -helical structures.
- a presentation structure is neuropeptide head activator.
- Bodenmuller et al. EMBO J. 5(8), 1825-1829 (1983) showed that neuropeptide head activator (HAv) dimerized to yield a biologically inactive form of the peptide at concentration as low as 10- 13 M, thus indicating extremely high self-binding affinity.
- Aldwin et al. U.S. Patent No. 5,491 ,074 observed that a fragment containing the last six amino acids of this peptide's carboxyl terminus (SKVILF) (SEQ ID NO:51) resulted in dimers that were even more stable than the HA itself.
- SKVILF carboxyl terminus
- the USPN 5,491,074 shows that the last amino acid of SKVILF, the F (phenylalanine), must be on the carboxyl terminus for a proper peptide dimerization activity. However, if F is not on the carboxyl terminus, it must be followed by one of two amino acids with free carboxyl group, E or D, to maintain the peptide dimerization. Therefore, if the dimerizing peptide positioned inside a carrier protein, 6-mer SKVILF sequence must be converted to 7-mer SKVILFE (SEQ ID NO:51) or SKVILFD (SEQ ID NO:53) sequences.
- F phenylalanine
- Linkers or spacers as known in the art are optionally placed between the HAv peptides and the variable ((X) n ) region and optionally placed at the amino and carboxy terminus of the structure.
- peptides in constrained conformations usually have higher affinity for a ligand than the same peptide in linear conformation.
- the constrained peptide has a higher protease resistance than the linear peptide as a result of the formation of a "rigid surface" structure.
- transfer of a constrained peptide as a cassette to a protein carrier will not dramatically change its original conformation (and consequently its binding activity) while a linear peptide is more likely to show a decrease in binding activity.
- the fusion partner is a targeting sequence.
- the localization of proteins within a cell is a simple method for increasing effective concentration.
- the concentration of a protein or polypeptide can also be simply increased by nature of the localization. For example, shuttling the fluorettes into the nucleus confines them to a smaller space thereby increasing the concentration.
- the ligand or target may simply be localized to a specific compartment.
- the targeting sequence can be fused to the protein partner as well.
- suitable targeting sequences include, but are not limited to, binding sequences capable of causing binding of the fluorette to a predetermined molecule or class of molecules while retaining activity of the fluorette, (for example by using enzyme inhibitor or substrate sequences to target a class of relevant enzymes); sequences signalling selective degradation, of itself or co-bound proteins; and signal sequences capable of constitutively localizing the fluorette to a predetermined cellular locale, including a) subcellular locations such as the Golgi, endoplasmic reticulum, nucleus, nucleoli, nuclear membrane, mitochondria, chloroplast, secretory vesicles, lysosome, and cellular membrane; and b) extracellular locations via a secretory signal. Particularly preferred is localization to either subcellular locations or to the outside of the cell via secretion.
- the targeting sequence is a nuclear localization signal (NLS).
- NLSs are generally short, positively charged (basic) domains that serve to direct the entire protein in which they occur to the cell's nucleus. Numerous NLS amino acid sequences have been reported including single basic NLS's such as that of the SV40 (monkey virus) large T Antigen (Pro Lys Lys Lys Arg Lys Val) (SEQ ID NO:54), Kalderon (1984), et al., Cell, 39:499-509; the human retinoic acid receptor- ⁇ nuclear localization signal (ARRRRP) (SEQ ID NO:55); NFKB p50 (EEVQRKRQKL SEQ ID NO:56); Ghosh et al., Cell 62:1019 (1990); NFKB p65 (EEKRKRTYE (SEQ ID NO:57; Nolan et al., Cell 64:961 (1991); and others (see for example Boulikas, J.
- NLSs incorporated into peptides or grafted onto proteins not normally targeted to the cell nucleus cause these peptides and proteins to be concentrated in the nucleus. See, for example, Dingwall, and Laskey, Ann, Rev. Cell Biol., 2:367- 390, 1986; Bonnerot, et al., Proc. Natl. Acad. Sci. USA, 84:6795-6799, 1987; Galileo, et al., Proc. Natl. Acad. Sci. USA, 87:458-462, 1990.
- the targeting sequence is a membrane anchoring signal sequence.
- membrane- bound fluorettes are useful for both the identification of important elements in these processes as well as for the discovery of effective inhibitors.
- the invention provides methods for presenting the fluorettes extracellularly or in the cytoplasmic space.
- a membrane anchoring region is provided at the carboxyl terminus of the peptide presentation structure.
- a membrane anchoring region is provided at the amino terminus of the peptide presentation structure.
- the amino terminal anchoring region functions as the anchoring region of a Type 2 glycoprotein.
- the fluorette is expressed on the cell surface and presented to the extracellular space, such that it can bind its target fluorophore.
- the binding of a fluorette, espescially when fused to a polypeptide or protein could confer a function on the cells expressing the fluorette.
- the cytoplasmic region could be neutral or could contain a domain that, when the fluorette is bound, confers a function on the cells (activation of a kinase, phosphatase, binding of other cellular components to effect function).
- the fluorette could be contained within a cytoplasmic region, and the transmembrane region and extracellular region remain constant or have a defined function.
- Membrane-anchoring sequences are well known in the art and are based on the geometry of mammalian transmembrane molecules. Peptides are inserted into the membrane based on a signal sequence (designated herein as ssTM) and require a hydrophobic transmembrane domain (herein TM). The transmembrane proteins are inserted into the membrane such that the regions encoded 5' of the transmembrane domain are extracellular and the sequences 3' become intracellular. Of course, if these transmembrane domains are placed 5' of the variable region, they will serve to anchor it as an intracellular domain, which may be desirable in some embodiments.
- ssTM signal sequence
- TM hydrophobic transmembrane domain
- ssTMs and TMs are known for a wide variety of membrane bound proteins, and these sequences may be used accordingly, either as pairs from a particular protein or with each component being taken from a different protein, or alternatively, the sequences may be synthetic, and derived entirely from consensus as artificial delivery domains.
- membrane-anchoring sequences including both ssTM and TM, are known for a wide variety of proteins and any of these may be used.
- Particularly preferred membrane-anchoring sequences include, but are not limited to, those derived from CD8, ICAM-2, IL-8R, CD4 and LFA-1.
- Useful sequences include sequences from: 1) class I integral membrane proteins such as IL-2 receptor beta-chain (residues 1-26 are the signal sequence, 241-265 are the transmembrane residues; see Hatakeyama et al., Science 244:551 (1989) and von Heijne et al, Eur. J. Biochem.
- insulin receptor beta chain (residues 1-27 are the signal, 957-959 are the transmembrane domain and 960-1382 are the cytoplasmic domain; see Hatakeyama, supra, and Ebina et al., Cell 40:747 (1985)); 2) class II integral membrane proteins such as neutral endopeptidase (residues 29-51 are the transmembrane domain, 2-28 are the cytoplasmic domain; see Malfroy et al., Biochem. Biophys. Res. Commun.
- CD8 and ICAM-2 are particularly preferred.
- the signal sequences from CD8 and ICAM-2 lie at the extreme 5' end of the transcript. These consist of the amino acids 1-32 in the case of CD8 (MASPLTRFLSLNLLLLGESILGSGEAKPQAP; (SEQ ID NO:59) Nakauchi et al., PNAS USA 82:5126 (1985) and 1-21 in the case of ICAM-2
- membrane anchoring sequences include the GPI anchor, which results in a covalent bond between the molecule and the lipid bilayer via a glycosyl-phosphatidylinositol bond for example in DAF (PNKGSGTTSGTTRLLSGHTCFTLTGLLGTLVTMGLLT (SEQ ID NO:63), with the bolded serine the site of the anchor; see Homans et al., Nature 333(6170):269-72 (1988), and Moran et al., J. Biol. Chem. 266:1250 (1991)).
- the GPI sequence from Thy-1 can be cassetted 3' of the fluorette in place of a transmembrane sequence.
- myristylation sequences can serve as membrane anchoring sequences. It is known that the myristylation of c-src recruits it to the plasma membrane. This is a simple and effective method of membrane localization, given that the first 14 amino acids of the protein are solely responsible for this function: MGSSKSKPKDPSQR (SEQ ID NO:64) (see Cross et al., Mol. Cell. Biol. 4(9): 1834 (1984); Spencer et al., Science 262:1019-1024 (1993), both of which are hereby incorporated by reference). This motif has already been shown to be effective in the localization of reporter genes and can be used to anchor the zeta chain of the TCR.
- This motif is placed 5' of the fluorette in order to localize it to the plasma membrane.
- Other modifications such as palmitoylation can be used to anchor fluorettes in the plasma membrane; for example, palmitoylation sequences from the G protein-coupled receptor kinase GRK6 sequence (LLQRLFSRQDCCGNCSDSEEELPTRL (SEQ ID NO:65), with the bold cysteines being palmitolyated; Stoffel et al., J. Biol. Chem 269:27791 (1994)); from rhodopsin
- KQFRNCMLTSLCCGKNPLGD (SEQ ID NO:66); Bamstable et al., J. Mol. Neurosci. 5(3):207 (1994)); and the p21 H-ras 1 protein (LNPPDESGPGCMSCKCVLS (SEQ ID NO:67); Capon et al., Nature 302:33 (1983)).
- the targeting sequence is a lysozomal targeting sequence, including, for example, a lysosomal degradation sequence such as Lamp-2 (KFERQ (SEQ ID NO:68); Dice, Ann. N.Y. Acad. Sci. 674:58 (1992); or lysosomal membrane sequences from Lamp-1 (MLIPIAGFFALAGLVLIVLIA YL/GRKRSHAGYQT1 (SEQ ID NO:69), Uthayakumar et al., Cell. Mol. Biol. Res.
- Lamp-2 KFERQ (SEQ ID NO:68)
- Lamp-1 MLIPIAGFFALAGLVLIVLIA YL/GRKRSHAGYQT1
- Lamp-2 (LVPIA VGAALA G VLIL VLLA Y /GLKH H H AGYEQ F (SEQ ID NO:70), Konecki et la., Biochem. Biophys. Res. Comm. 205:1-5 (1994), both of which show the transmembrane domains in italics and the cytoplasmic targeting signal underlined).
- the targeting sequence may be a mitrochondrial localization sequence, including mitochondrial matrix sequences (e.g. yeast alcohol dehydrogenase III;
- MLRTSSLFTRRVQPSLFSRNILRLQST SEQ ID NO:71 ); Schatz, Eur. J. Biochem. 165:1-6 (1987)); mitochondrial inner membrane sequences (yeast cytochrome c oxidase subunit IV;
- MLSLRQSIRFFKPATRTLCSSRYLL SEQ ID NO:72; Schatz, supra; mitochondrial intermembrane space sequences (yeast cytochrome d ;
- mitochondrial outer membrane sequences yeast 70 kD outer membrane protein; MKSFITRNKTAILATVAATGTAIGAYYYYNQLQQQQQRGKK (SEQ ID NO:74);
- the target sequences may also be endoplasmic reticulum sequences, including the sequences from calreticulin (KDEL; Pelham, Royal Society London Transactions B; 1-10 (1992)) or adenovirus E3/19K protein (LYLSRRSFIDEKKMP (SEQ ID NO:75); Jackson et al., EMBO J. 9:3153 (1990)).
- KDEL calreticulin
- LYLSRRSFIDEKKMP SEQ ID NO:75
- targeting sequences also include peroxisome sequences (for example, the peroxisome matrix sequence from Luciferase; SKL; Keller et al., PNAS USA 4:3264 (1987)); farnesylation sequences (for example, P21 H-ras 1 ; LNPPDESGPGCMSCKCVLS (SEQ ID NO:76), with the bold cysteine farnesylated; Capon, supra); geranylgeranylation sequences (for example, protein rab-5A; LTEPTQPTRNQCCSN (SEQ ID NO:77), with the bold cysteines geranylgeranylated; Farnsworth, PNAS USA 91 :11963 (1994)); or destruction sequences (cyclin B1; RTALGDIGN (SEQ ID NO:78); Klotzbucher et al., EMBO J. 1 :3053 (1996)).
- peroxisome sequences for example, the peroxisome matrix sequence from Luciferase; SKL; Keller et al.,
- the targeting sequence is a secretory signal sequence capable of effecting the secretion of the fluorette.
- secretory signal sequences There are a large number of known secretory signal sequences which are placed 5' to the fluorette sequence and are cleaved from the peptide region to effect secretion into the extracellular space. Secretory signal sequences and their transferability to unrelated proteins are well known, e.g., Silhavy, et al. (1985) Microbiol. Rev. 49, 398-418. This is particularly useful to generate a fluorette that is expressed at the surface of a cell.
- a fusion product is configured to contain, in series, secretion signal peptide-presentation structure-flourette-presentation structure.
- target cells grown in the vicinity of cells caused to express the fluorettes are bathed in secreted fluorette.
- Target cells exhibiting a phenotypic change in response to the presence of a fluorette, or internalization of the fluorette and binding to intracellular targets are localized by any of a variety of methods, such as, FRET analysis (Selvin et al. Methods Enzymol. 246:300-334 (1995)) as described below.
- Suitable secretory sequences are known, including signals from IL-2
- a particularly preferred secretory signal sequence is the signal leader sequence from the secreted cytokine IL-4, which comprises the first 24 amino acids of IL-4 as follows: MGLTSQLLPPLFFLLACAGNFVHG (SEQ ID NO:83).
- the fusion partner is a rescue sequence.
- a rescue sequence is a sequence which may be used to purify or isolate the fluorette (or, in some cases, the nucleic acid encoding it).
- peptide rescue sequences include purification sequences such as the His 6 tag for use with Ni affinity columns and epitope tags for detection, immunoprecipitation or FACS (fluorescence-activated cell sorting).
- Suitable epitope tags include myc (for use with the commercially available 9E10 antibody), the BSP biotinylation target sequence of the bacterial enzyme BirA, flu tags, iacZ, and GST.
- a fluorette sequence functions as a rescue sequence.
- the fluorette because it binds a fluorophore dye can be used to purify or isolate a molecule to which it is fused or attached by affinity chromatography using fluorophore dye columns. If the fluorette alters the excitation or emission spectrum of the bound fluorophore dye, as described below, this difference can be used to monitor attachment and/or elution of the fluorette from the affinity column.
- the fluorette/dye complex can be used in FACS.
- a linker joining the fluorette to its fusion partner also contains a convenient site or sites to seperate the fluorette from the fusion partner, such as, a unique protease recognition sequences.
- the affinity column can contain antibody reactive with the fluorette.
- the fusion partner is a stability sequence to confer stability to the fluorette.
- fluorettes may be stabilized by the incorporation of glycines after an amino-terminal methionine (MG or MGGO), for protection of the fluorette to ubiquitination as per Varshavsky's N-End Rule, thus conferring long half-life in the cytoplasm.
- MG or MGGO amino-terminal methionine
- two pralines at the C-terminus impart upon peptides resistance to carboxypeptidase action.
- the presence of two glycines prior to the prolines impart both flexibility and prevent structure initiating events in the di- proline to be propagated into the fluorette structure.
- preferred stability sequences are as follows: MG(X) n GGPP (SEQ ID NO:84), where (X) n is a fluorette of any amino acid and n is an integer of at least about 8, as outlined above for fluorette length.
- the fusion partner is a dimerization sequence.
- a dimerization sequence allows the non-covalent association of one fluorette to another fluorette, with sufficient affinity to remain associated under normal physiological conditions.
- the dimers may be homo- or heterodimers.
- Dimerization sequences may be a single sequence that self-aggregates, or two sequences. That is, a first fluorette with dimerization sequence 1 , and a second fluorette with dimerization sequence 2, such that upon introduction into a cell and expression of the nucleic acids, dimerization sequence 1 associates with dimerization sequence 2 to form new random peptide structures.
- dimerization sequences can be used as presentation structures. That is, by putting a first dimerization sequence at one terminus of the fluorette, and a second dimerization sequence at the other terminus, similar to some other presentation structures, a "cyclized" fluorette can be made.
- dimerization sequences will encompass a wide variety of sequences. Any number of protein-protein interaction sites are known. In addition, dimerization sequences may also be elucidated using standard methods such as the yeast two hybrid system, and traditional biochemical affinity binding studies, or even using the present methods.
- the fusion partners may be placed anywhere (i.e. N-terminal, C-terminal, internal) in the structure as the biology and activity permits, although in general, N- or C-terminal fusions are preferred to fusions internal to the fluorette sequence.
- a fluorette occupies an internal position within the fusion partner as the biology and activity permits. This will allow a means to measure access of the fluorette for its fluorophore dye as a means of determining structure and function of the region in which the fluorette resides.
- the fusion partner includes a linker or tethering sequence.
- Linker sequences between various targeting sequences may be desirable to allow the candidate agents to interact with potential targets unhindered.
- useful linkers include glycine- serine polymers (including, for example, (GS) n (SEQ ID NO:85), (GSGGS) n (SEQ ID NO:86) and (GGGS) n (SEQ ID NO:87), where n is an integer of at least one), glycine-alanine polymers, alanine-serine polymers, and other flexible linkers such as the tether for the shaker potassium channel, and a large variety of other flexible linkers, as will be appreciated by those in the art. Glycine-serine polymers are preferred since both of these amino acids are relatively unstructured, and therefore may be able to serve as a neutral tether between components.
- linkers such as these may also be used in some embodiments between fluorettes and the moiety to which they are fused.
- linkers can also be sequences that are derived from other proteins and have no structure or an assumed structure.
- linkers distance the fluorette from a molecule to which they are attached, for example, a fusion protein.
- the fusion partners may be modified, randomized, and/or matured to alter the presentation orientation of the fluorette.
- determinants at the base of the loop may be modified to slightly modify the internal loop tertiary structure, which maintains the fluorette amino acid sequence.
- combinations of fusion partners are used.
- any number of combinations of presentation structures, targeting sequences, rescue sequences, and stability sequences may be used, with or without linker sequences.
- the fluorette is fused to a target analyte, for example, to monitor or follow the target analyte, as is more fully described below.
- target analyte or “analyte” or grammatical equivalents herein is meant any molecule, compound or particle to be detected.
- a large number of analytes may be detected using the present methods; basically, any target analyte to which a fluorette may be attached may be detected using the methods of the invention.
- Suitable analytes include organic and inorganic molecules, including biomolecules.
- the analyte may be an environmental pollutant (including pesticides, insecticides, toxins, etc.); a chemical (including solvents, polymers, organic materials, etc.); therapeutic molecules (including therapeutic and abused drugs, antibiotics, etc.); biomolecules (including hormones, cytokines, proteins, lipids, carbohydrates, cellular membrane antigens and receptors (neural, hormonal, nutrient, and cell surface receptors) or their ligands, etc); whole cells (including procaryotic (such as pathogenic bacteria) and eukaryotic cells, including mammalian tumor cells); viruses (including retroviruses, herpesviruses, adenoviruses, lentiviruses, etc.); and spores; etc.
- Particularly preferred analytes are proteins.
- the target analyte is a protein and the fluorette is made as a fusion protein, using techniques well known in the art.
- the nucleic acid encoding the fluorette is linked in-frame with a nucleic acid encoding a target protein to produce a fusion nucleic acid.
- fusion proteins are produced by culturing a host cell transformed with an expression vector containing the fusion nucleic acid, under the appropriate conditions to induce or cause expression of the fusion protein.
- the conditions appropriate for fusion protein expression will vary with the choice of the expression vector and the host cell, and will be easily ascertained by one skilled in the art through routine experimentation.
- the use of constitutive promoters in the expression vector will require optimizing the growth and proliferation of the host cell, while the use of an inducible promoter requires the appropriate growth conditions for induction.
- the timing of expression is important.
- fluorettes can be produced by in vitro transcription of the encoding nucleic acid and translation of the RNA transcript, as known in the art.
- the target analyte is other than a protein, and the fusion of the fluorette to the target analyte is generally done chemically.
- the fluorette and the target analyte are attached through the use of functional groups on each that can then be used for attachment.
- Preferred functional groups for attachment are amino groups, carboxy groups, oxo groups and thiol groups. These functional groups can then be attached, either directly or indirectly through the use of a linker.
- Linkers are well known in the art; for example, homo-or hetero-bifunctional linkers as are well known (see 1994 Pierce Chemical Company catalog, technical section on cross-linkers, pages 155-200, incorporated herein by reference).
- carboxyl groups may be derivatized using well known linkers (see the Pierce catalog).
- linkers see the Pierce catalog.
- carbodiimides activate carboxyl groups for attack by good nucleophiles such as amines (see Torchilin et al., Critical Rev. Therapeutic Drug Carrier Systems, 7(4):275-308 (1991), expressly incorporated herein).
- Proteinaceous species may also be attached using other techniques known in the art, for example for the attachment of antibodies to polymers; see Slinkin et al., Bioconj. Chem. 2:342-348 (1991);
- the fluorette will bind to Texas Red.
- Suitable fluorettes in this embodiment include, but are not limited to, KHVQYWTQMFYS (SEQ ID N0:1); DFLQWKLARQKP
- KNVQYWTQMFYT (SEQ ID NO:17); KHVQYWTHMFYT (SEQ ID NO:18); KHVQYWTQMFYT
- RTIWEPKEASNHT SEQ ID NO:105
- WSKMGHTVT SEQ ID NO:106
- RWTWEPISE SEQ ID NO:107
- GNQKCLQHNRCST SEQ ID NO:108
- SQTWSFPEH SEQ ID NO:109
- EPMARPWERKQDR (SEQ ID NO:110); and GTLSATRPYGRQW (SEQ ID NO:111).
- the fluorette will bind to Rhodamine.
- Suitable fluorettes in this embodiment include, but are not limited to, IPHPPMYWTRVF (SEQ ID NO:3); IPHRPMYWTPVF (SEQ ID NO:22); and LPHPPMYWTRVF (SEQ ID NO:23).
- the fluorette will bind to Oregon Green 514.
- Suitable fluorettes in this embodiment include, but are not limited to, HGWDYYWDWTAW (SEQ ID NO:4); ASDYWDWEWYYS (SEQ ID NO:5); YPNDFEWWEYYF (SEQ ID NO:6); HTSHISWPPWYF (SEQ ID NO:7); LEPRWGFGWWLK (SEQ ID NO:8); QYYGWYYDHNFW (SEQ ID NO:9); YMYDEYQYWNFW (SEQ ID NO:10); HEWEYYWDWTAW (SEQ ID NO:24); HEWDYYWDWTAW (SEQ ID NO:25); HGWDYYWDWTDW (SEQ ID NO:26); HGWDYYWDWTPW (SEQ ID NO:27); HGWDYYWDWTTW (SEQ ID NO:28); HGWDYNWDWTAW (SEQ ID NO:29); and QGWDYYWDW
- the fluorette will bind to Fluorescein.
- Suitable fluorettes in this embodiment include, but are not limited to, YPNDFEWWEYYF (SEQ ID NO:6); ASDYWDWEWYYS (SEQ ID NO:5); WYDDWNDWHAWP (SEQ ID NO:11); WHMSPSWGWGYW (SEQ ID NO:12); HMSWWEFYLVPP (SEQ ID NO:13); YWDYSWHYYAPY (SEQ ID NO:14); YPNEFDWWDYYY (SEQ ID NO:31 ); YPNDFEWWDYYY (SEQ ID NO:32); YHNDYEWWEYYY (SEQ ID NO:33); YPNDFEWWEYYY (SEQ ID NO:34); YPNDFDWWEYYL (SEQ ID NO:35); YTHDYEWWEYYF (SEQ ID NO:36); YPNDYEWWEYYF (SEQ ID NO:
- a peptide is a fluorette if the overall homology of the peptide sequence to the amino acid sequences shown above (SED ID NOS 1-40 and 104-110) is preferably greater than about 70%, more preferably greater than about 75% even more preferably greater than about 80% and most preferably greater than 90%, with homologies of greater than 95 to 98% being especially preferred.
- Homology in this context means sequence similarity or identity, with identity being preferred.
- This homology will be determined using standard techniques known in the art, including, but not limited to, the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biool. 48:443 (1970), by the search for similarity method of Pearson & Lipman, PNAS USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Drive, Madison, WI), the Best Fit sequence program described by Devereux et al., Nucl. Acid Res. 12:387-395 (1984), preferably using the default settings, or by inspection.
- percent identity is calculated by FastDB based upon the following parameters: mismatch penalty of 1 ; gap penalty of 1 ; gap size penalty of 0.33; and joining penalty of 30, "Current Methods in Sequence Comparison and Analysis,” Macromolecule Sequencing and Synthesis, Selected Methods and Applications, pp 127-149 (1988), Alan R. Liss, Inc.
- PILEUP creates a multiple sequence alignment from a group of related sequences using progressive, pairwise alignments. It can also plot a tree showing the clustering relationships used to create the alignment. PILEUP uses a simplification of the progressive alignment method of Feng & Doolittle, J. Mol. Evol. 35:351-360 (1987); the method is similar to that described by Higgins & Sharp CABIOS 5:151-153 (1989).
- Useful PILEUP parameters including a default gap weight of 3.00, a default gap length weight of 0.10, and weighted end gaps.
- Another example of a useful algorithm is the BLAST algorithm, described in Altschul et al., J. Mol.
- WU-BLAST-2 uses several search parameters, most of which are set to the default values.
- the HSP S and HSP S2 parameters are dynamic values and are established by the program itself depending upon the composition of the particular sequence and composition of the particular database against which the sequence of interest is being searched; however, the values may be adjusted to increase sensitivity.
- a % amino acid sequence identity value is determined by the number of matching identical residues divided by the total number of residues of the "shorter" sequence in the aligned region.
- the "longer" sequence is the one having the most actual residues in the aligned region (gaps introduced by WU-Blast-2 to maximize the alignment score are ignored).
- Gapped BLAST uses BLOSUM-62 substitution scores; threshold T parameter set to 9; the two-hit method to trigger ungapped extensions; charges gap lengths of k a cost of 10+/ ; X u set to 16, and X g set to 40 for database search stage and to 67 for the output stage of the algorithms. Gapped alignments are triggered by a score corresponding to ⁇ 22 bits.
- a percent amino acid sequence identity value is determined by the number of matching identical residues divided by the total number of residues of the "longer" sequence in the aligned region.
- the "longer” sequence is the one having the most actual residues in the aligned region (gaps introduced by WU-Blast-2 to maximize the alignment score are ignored).
- percent sequence identity is determined by inspection in which only identities are scored positively (+1) and all forms of sequence variation including gaps are assigned a value of "0". Percent sequence identity can be calculated, for example, by dividing the number of matching identical residues by the total number of residues of the "shorter" sequence in the aligned region and multiplying by 100. The "longer" sequence is the one having the most actual residues in the aligned region.
- amino acid sequences of the fluorettes may be modified as needed. Sequence modifications include substitutions, deletions, insertions or any combination thereof may be used to arrive at a final derivative. Generally these changes are done on a few amino acids to minimize the alteration of the molecule. However, larger changes may be tolerated in certain circumstances. When small alterations in the characteristics of the fluorette are desired, substitutions are generally made in accordance with the following chart: Chart 1
- substitutions that are less conservative than those shown in Chart I, although these generally are not preferred.
- substitutions may be made which more significantly affect the structure of the fluorette backbone in the area of the alteration, for example the alpha-helical or beta-sheet structure; the charge or hydrophobicity of the molecule; or the bulk of the side chain.
- substitutions which in general are expected to produce the greatest changes in the fluorette's properties are those in which (a) a hydrophilic residue, e.g. seryl or threonyl, is substituted for (or by) a hydrophobic residue, e.g.
- leucyl isoleucyl, phenylalanyl, valyl or alanyl
- a cysteine or proline is substituted for (or by) any other residue
- a residue having an electropositive side chain e.g. lysyl, arginyl, or histidyl
- an electronegative residue e.g. glutamyl or aspartyl
- a residue having a bulky side chain e.g. phenylalanine, is substituted for (or by) one not having a side chain, e.g. glycine.
- not more than about three substitutions or deletions will be made, and that the change will not be more than about 20 number %, usually not more than about 10 number %, of the number of amino acids in the fluorette, although in some instances higher numbers of alterations may be made.
- conservative substitutions as known in the art, including substitutions within the large hydrophobic group isoleucine, leucine, valme and phenylalanine, between serine and threonme, glycine and alanine, asparagme and glutamine, aspartic acid and glutamic acid, or lysine, arginine and histidme
- non-conservative alterations are done
- such libraries are based on, for example, either bactenophage (Matthews and Wells Science 260 1113-1117 (1993), Koivunen et al Biotechnology 13 265-270 (1995), Yu and Smith Methods Enzymol 267 3- 27 (1996), Harrison et al Methods Enzymol 267 83-109 (1996), Rebar and Pabo Science 263
- fluorettes are created, isolated, or selected from aptamer library phage display approaches Such libraries are based on, for example, M13 filamentous bactenophage (Smith Science 228 1315-1317 (1985), Cwirla et al Proc Natl Acad Sci U S A 87 6378-6382 (1990), Devlin et al Science 249 404-406 (1990), Scott and Smith Science 249 386-390 (1990))
- fluorettes are identified by screening a phage display peptide library that contains a combinatorial library of peptides interposed betwen the leader sequence and the ammo terminus of mature form of bactenophage M13amp9 minor coat protein, pill
- the recombinato ⁇ al library can be produced by a number of methods as known in the art
- the library is produced by annealing and cloning an ohgonucleotide library of sequences into the M13amp9 pill gene
- Annealing of the ohgonucleotide library to produce double-stranded DNA preferably produces "sticky ends" to facilitate directional cloning into the appropriate reading frame of the M13amp9
- the annealed ohgonucleotide library contains unique restriction enzyme sites, which are digested to produce "sticky ends" to facilitate directional cloning
- the ohgonucleotide library preferably also encodes an in-frame linker, tethering sequence, or spacer as described herein The function of the linker is to decrease or minimize stenc hindrance and promote accessibility of the fluorette for its fluorophore dye The linker also promotes structural and functional independence of the fluorette Phage particles bea ⁇ ng the peptide
- Cloning and expression of the ohgonucleotide library produces a library of peptides either directly fused to the pill protein or, preferably, fused via a linker or spacer
- the linker or spacer can be, for example, sequence, as described herein, interposed between the fluorette and the pill protein sequences
- the nucleic acids which give rise to the fluorettes are chemically synthesized, and thus may incorporate any nucleotide at any position Thus, when the nucleic acids are expressed to form peptides, any am o acid residue may be incorporated at any position
- the synthetic process can be designed to generate randomized nucleic acids, to allow the formation of all or most of the possible combinations over the length of the nucleic acid, thus forming a library of randomized nucleic acids and peptides
- random DNA fragments may be made from fragmentation of genomic DNA, followed by sizing, and hgation into an appropriate vector for expression and selection
- the library should provide a sufficiently structurally diverse population of randomized expression products to effect a probabilistically sufficient range to allow isolation of a fluorette Accordingly, a library must be large enough so that at least one of its members will have a structure that gives it affinity for a fluorophore dye Although it is difficult to gauge the required absolute size of a library, nature provides a hint with the immune response a diversity of 10 7 -10 8 different antibodies provides at least one combination with sufficient affinity to interact with most potential antigens faced by an organism Published in vitro selection techniques have also shown that a library size of 10 7 to 10 8 is sufficient to find structures with affinity for the target A library of all combinations of a peptide from about 7 to 20 ammo acids in length has the potential to code for 20 7 (10 9 ) to 20 20 Thus, with libraries of 10 7 to 10 8 per ml of phage particles the present methods allow a "working" subset of a theoretically complete interaction library for 7 amino acids, and a subset of shapes for the 20 20 library. Thus, in a preferred
- NNK NNK
- K T or G
- bactenophage expressing fluorettes are selected by biopanning, which consists of four sequential steps: i) phage binding with a fluorophore dye carrier, ii) removal of unbound or weakly bound phage, iii) elution of bound phage and (iv) amplification of bound phage. Certain steps can be omitted, for example, such as washing and amplification if the peptide library is expressed in eukaryotic or mammalian cells and fluorescence is detected and cells are shorted according to fluorescence or spectral shifts.
- the amplified phage are used for the subsequent round(s) of biopanning against the corresponding fluorophore dye carrier until apparent enrichment for binding is observed over background.
- phage bearing sequences that bind specifically to a fluorophore dye can be identified.
- the individual phage are isolated, amplified and the sequence of the fluorette can be determined by various methods as known in the art.
- eukaryotic or prokaryotic cells expressing a peptide library on their surface can be sorted by FACS and/or magnetic beads to isolate cells expressing fluorettes.
- the fluorophore dyes can be bound to solid-phase carriers.
- the dyes are covalently attached to a target bead. This facilitates washing and removal of non-specifically bound or weakly bound phage.
- a linker or spacer molecule is interposed between the fluorophore dye and the target bead, for example, succinimidy esters and derivatives of fluorophores.
- a spacer molecule increases the accessibility of the fluorophore dye and minimizes potential steric hindrance that may interfere with the interactions between the fluorophore dye and the bactenophage particles that bear the peptide library.
- the number of fluorophore dye molecules bound to the carrier will vary. In general, there are up to about 1 micromole. Higher or lower amounts of dye can be attached per ml of carrier beads, as needed, for example to increase or decrease the stringency of the biopanning conditions.
- a fluorette Once a fluorette is identified, it can be mutagenized or derivatized to isolate fluorettes with altered properties.
- the derivatize fluorettes have a higher affinity or specificity, thereby, providing, for example, increased sensitivity for the assay or system in which the fluorette is employed. This also allows the use of lower amounts of fluorescent dye, thereby, limiting toxicity of the fluorescent dye to cells, if needed.
- affinity maturation (Yu and Smith, supra) can be used to produce mutant or derivative fluorettes with improved affinities over their corresponding parental fluorettes.
- a second ohgonucleotide library is produced that is, preferabbly, based. That is, some positions within the sequence are either held constant, or are selected from a limited number of possibilities.
- the nucleotides or amino acid residues are randomized within a defined class, for example, of hydrophobic amino acids, hydrophilic residues, sterically biased (either small or large) residues, towards the creation of cysteines, for cross-linking, pralines for SH-3 domains, serines, threonines, tyrosines or histidines for phosphorylation sites, etc., or to purines, etc.
- the amino acid sequences of the fluorettes are subjected to biased mutagenesis at a desired mutagenesis rate using a number of methods as known in the art.
- the sequences can be mutagenized by systemmatic alteration of the codons encoding the fluorettes.
- Ohgonucleotide mutagenesis is preferablly, performed during the synthesis of the ohgonucleotide library.
- specific nucleotides such as A and C, can be omitted from the third position of each codon.
- the ohgonucleotide library is preferably annealed and cloned into an expression vector of choice.
- the biopanning conditions are preferably altered to be more stringent by, for example, changing one or more of the following conditions. This also provides a method to maximize selection against the parental fluorette.
- concentration of the fluorophore dye bound to the carrier beads can be decreased.
- the phage concentration represented in the binding step and/or the binding time also can be reduced.
- stringency of the washing conditions is increased. Washing stringency can be increased by, for example, increasing the volume of washing buffer per ml of carrier beads, increasing the wash temperature, altering the ionic strength or pH of the wash buffer, increasing the detergent concentration or by using a stronger, ionizing detergent.
- Fluorette binding to a fluorophore dye can be assessed in several ways. For example, when a phage display system is used, binding of the bacteriophage-bearing peptide library to the fluorophore dye-carrier can be determined by comparing the infectious particle titers of input phage to eluted phage. To measure phage-fluorophore dye binding in solution, a known concentration of free fluorophore dye is mixed with a known number of purified phage particles. The number of particles is preferably calculated from the optical densities of the purifed phage at 260 nm and 280 nm but other methods, such as, infectious titer can be used.
- Phage-fluorophore dye complexes are separated by, for example, precipitation to remove unbound dye, spotted onto a solid-support filter, such as, nitrocellulose and scanned for fluorescence.
- Other methods to remove unbound dye include, for example, competition with related molecules, washing, and increased stringency
- controls using phage particles that do not display recombinatorial library sequences are run in parallel.
- specific to nonspecific binding ratios also can be quantitated.
- Fluorette/fluorophore dye dissociation constants can be determined in several ways. For example, when a phage display system is used, phage-fluorophore dye dissociation constants can be determined by, for example, incubating for several hours subsaturating amounts of phage with a fluorophore dye bound to a carrier, for example, a bead as described above. The bead suspensions are removed, for example, by centrifugation, and the unbound phage in the supernatants can be titrated. Other methods for measuring unbound phage are known in the art, for example, visualization. Dissociation constants can be measured via a standard linear Scatchard plot. Nonspecific background binding is determined using phage that does not express fluorette sequences.
- fluorettes are encoded by nucleic acids and produced by recombinant molecular biology techniques (Sambrook et al (1989) Molecular Cloning A Laboratory Manual (2nd Edition) Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, Ausubel et al (1994) Current Protocols in Molecular Biology Massachusettes General Hospital and Harvard Medical School Boston, MA)
- nucleic acids By "nucleic acids” herein is meant a nucleic acid, DNA or RNA depending on the delivery or expression vehicle or vector used, which can be manipulated to express fluorettes, that is, the nucleic acids encoding the fluorettes and the fusion partners and linkers if present
- the nucleic acids will also generally contain enough extra sequence to effect translation or transcription, as necessary
- the nucleic acid generally contains cloning sites which are placed to allow in frame expression of the fluorettes, and any fusion partners, if present, such as presentation structures
- any fusion partners if present, such as presentation structures
- the nucleic acids are introduced and expressed within the cells to produce fluorettes
- introduction into or grammatical equivalents herein is meant that the nucleic acids enter the cells in a manner suitable for subsequent expression of the nucleic acid
- Exemplary methods include CaP0 4 precipitation, hposome fusion, hpofectm®, electroporation, viral infection, etc
- the candidate nucleic acids may stably integrate into the genome of the host cell (for example, with retroviral introduction), or may exist either transiently or stably in the cytoplasm (i e through the use of traditional plasmids, utilizing standard regulatory sequences, selection markers, etc )
- retroviral vectors capable of transfectmg such targets are preferred
- the fluorettes functions within the cell in which they are expressed
- fluorettes may be expressed within a cell or secreted from a cell, and purified If desired, the fluorette can be introduced into another cell by electroporation, calcium phosphate precipitation, microinjectioin, hposome fusion, hpofectm, viral infection, etc
- Fluorettes also may be produced in vitro by transcription/translation reactions Alternatively, fluorettes are chemically synthesized using any of a number of methods.
- the present invention provides a complex or composition of a fluorette bound to a fluorophore dye.
- the binding of the fluorette to the fluorophore dye leads to four possible outcomes in regards to the excitation and emission spectra of the fluorophore dye i) little to no change in the fluorophore emission or excitation spectra, ii) change in fluorophore emission, iii) change in fluorophore excitation and (iv) change in both fluorophore emission and excitations.
- binding of the fluorette to the fluorophore dye may prevent fluorophore excitation or emission.
- the fluorophore dye no longer fluoresces when bound to the fluorette.
- the excitation spectrum and/or the emission spectrum of the fluorophore dye is shifted, to a shorter or longer wavelength.
- the excitation spectrum and/or emission spectrum can be broadened.
- the excitation spectrum is altered up to about 5 nm, about 10 nm, being preferred, 20 nm particularly preferred, and about 100 nm being especially preferred.
- Fluorettes in their various forms find use in detector systems and various types of assays and techniques using a large set of potential fluorophore dyes, for example as, in detection of viral delivery systems, diagnostics, high-throughput assays.
- compositions find use in a number of applications. These applications include binding a fluorophore dye to the fluorette, removing unbound dye and detecting fluorescence.
- the emission and/or excitation spectrum of the fluorophore dye is altered when bound to a fluorette. Therefore, it is not necessary to remove unbound dye.
- FRET fluorescence resonance energy transfer
- FRET applications based on fluorette/fluorophore dye interactions provide methods to demonstrate the proximity or interactions of two or more molecules. These molecules include, for example, biological molecules, such as proteins, lipids, nucleic acids, carbohydrates. In another embodiment, FRET can be applied to detect or induce the localized activation of a produrg
- the interactions of two or more proteins, each containing a unique fluorette sequence can be demonstrated as follows. First, the fluorophore dyes are bound by their corresponding fluorettes. Next, one of the fluorette/fluorophore dye complexes or donor complex is excited and fluoresces. When the two proteins containing the fluorette sequences are in close proximity or in some way have interacted, the emitted light of the first donor complex causes the second fluorette/fluorophore dye complex (acceptor) to fluoresce.
- FRET fluorette/fluorophore dye complexes that are covalently or associately linked to target biomaterials via small ligands.
- the demonstration of FRET as described above indicates an interaction or the proximity of the target biomaterials when bound to their respective ligands.
- Other applications include, "trigger dependent FRET", in which the use and design of trigger molecules, such as, heavy metal ions, drugs, etc., that specifically bind to the ligand or target biomaterials, causing dissociation of one or more of the fluorette/dye complexes from the target biomaterials and a decrease or loss of FRET.
- FRET may also be employed to detect intramolecular interactions or events, such as, changes in molecular structure that occurs in a molecule with the binding and/or dissociation of a ligand.
- double or higher order fluorettes may be linked, for example, via a rigid connector, such as polyalanine or polyserine, to provide the correct angle of orientation of corresponding donor and acceptor fluorette/fluorophore dye complexes.
- a rigid connector such as polyalanine or polyserine
- This may be of importance for efficient and quantitative FRET output.
- it may be desirable for the spacer to contain a peptide sequence or other material which, upon binding a specific fluorophore dye, brings the donor and acceptor comlexes into proximity such that FRET can ensue.
- FRET applications also include dual fluorophore dye quenching due to fluorette binding.
- fluorettes specific for donor and acceptor fluorophores are joined by a protease cleavable spacer. This fluorette dimer is bound to its two fluorophore dyes targets and FRET ensues as described above. However, FRET decreases after protease cleavage of the fluorette dimer.
- novel assays are based on fluorophore dye quenching due to its binding of a specific fluorette.
- a target protein is labeled in vitro by a fluorophore dye and is assembled into a complex particle or structure with other materials (e.g., other proteins, DNA or RNA) whose conformation or structure is to be investigated.
- other materials e.g., other proteins, DNA or RNA
- the addition of a specific fluorette after the complex is assembled and measuring fluoresence indicates if the fluorette had access (binding) or no access (no binding) to its target dye.
- Novel reporter gene assays based on fluorette-induced Stokes shift changes also can be created
- a fluorette fused with a given carrier protein can be used as a gene activity reporter for the presence of the protein Cell extracts, or living cells expressing the protein, can be monitored for fluorette activity when the specific fluorophore dye is bound by the peptide Binding of the fluorophore dye by the fluorette/peptide modifies the excitation and/or emitted wavelength permitting specific detection of the expressed protein Consequently, the more Stokes shift changes introduced by binding of peptide the more sensitive the assay can become The simplicity of such an approach surpasses the currently available enzymatic reporter gene assays (e g , luciferase and beta-galactosidase assays)
- Fluorophore Dve Carriers Four fluorophore dyes, Texas Red, Fluorescein, Rhodamine Red and Oregon Green 514, were chosen, for selection of fluorettes from a phage display library (Example 2) The chemical structures of the dye conjugates are shown in Figure 1
- the first three dyes, Texas Red, Fluorescein and Rhodamine Red fall into one group (i) they have a relatively high molar extinction coefficient for absorption and excellent quantum fluorescence yields (Haugland supra), (n) they have non-overlapping spectral characteristics, (in) they have the potential for cross-quenching and/or FRET analysis
- the fourth dye, Oregon Green 514, related structurally to Fluorescein was chosen to determine if structure-function relationships could be discerned between fluorette peptides that bound related dyes
- fluorophore dyes 6-(fluoresce ⁇ n-5-(and-6)-carboxam ⁇ do)hexano ⁇ c acid succinimidyl ester (5(6)-SFX), "mixed isomers", Oregon Green 514 carboxylic acid, succinimidyl ester, Rhodamine Red-X, succinimidyl ester, “mixed isomers” and Texas Red-X, succinimidyl ester, “mixed isomers” were purchased from Molecular Probes
- a phage display peptide library was screened that contained a combinatorial library of 12-mer peptides fused via a short glycine linker spacer (GGG) to the ammo-terminus of a minor coat pill protein (5 copies per particle, Li et al (1980) J Biol Chem 255 10331-10337) of the filamentous bactenophage M13mp19 (Ph.D. phage display, New England Biolabs). During phage maturation, the leader secretory sequence is removed. This results in the 12-mer peptide positioned immediately at the amino-terminus of the mature protein.
- GGG short glycine linker spacer
- E. coli ER2537 strain [F' lacl q ⁇ (lacZ)M15 proA + B + /fhuA2 supE thi ⁇ (lac-proAB) ⁇ (hsdSM-mcrB)5 (rk " mk “ mcrBC- )] and E.coli TG-1 strain [supE thi-1 ⁇ (lac-proAB) ⁇ (mcrB-hsdSM)5 (rk " mk “ ) (F' traD36 proAB lacl q Z ⁇ M15)] were purchased from New England Biolabs and Stratagene, respectively, and used as bactenophage M13mp19 hosts. All bacteriological techniques were performed as described (Sambrook et al., supra; Ausubel et al., supra).
- Each biopanning round consisted of four sequential steps: (i) phage binding with a fluorophore dye carrier, (ii) washing unbound phage from the beads, (iii) nonspecific elution of bound phage and (iv) amplification of bound phage.
- the Ph.D. -12 phage display peptide library (based on modified M13mp19 bactenophage, 1.9x10 9 independent transformants) as a part of the Ph.D. -12 phage display peptide library kit was purchased from New England Biolabs. All procedures were carried out at room temperature unless noted.
- the bound phage were nonspecifically eluted by 1ml of 0.2M glycine-HCI, pH 2.2 + 1 mg/ml BSA (elution buffer) for 10' and the eluates were immediately adjusted to a neutral pH by 0.15ml of 1M Tris-HCI, pH 9.1. Bound phage yields were determined by a titration of the eluates on the ER2537 host strain (Sambrook et al., supra). Amplification step: all bound phage (1.1ml) were added to 27 ml of 1/100 diluted overnight ER2537 culture and amplified for 4.5hr at 37°C with vigorous shaking.
- the amplified phage were precipitated from cell supernatants by 1/5 V of 20% PEG + 2.5M NaCI at 4°C, re-precipitated again and, finally, suspended in 0.5ml TBS + 0.05% sodium azide.
- the resultant " 50-fold concentrated amplified phage were stored at 4°C and their titers usually were in the range 0.5-1.5x10 13 pfu/ml.
- amplified phage were adjusted to 50% glycerol and stored at -20°C.
- the amplified phage were used for the next biopanning rounds against the corresponding fluorophore dye carrier, if necessary, until apparent enrichment for binding was observed over background.
- Eluted phage from round 4 selected against four different fluorophore dye carriers are termed herein as TR-4, RhR-4, OG-4 and Flu-4 (standing for Texas Red, Rhodamine Red, Oregon Green 514 and Fluorescein carriers, respectively).
- the amplified phage from round 1 were further selected against the corresponding fluorophore dye carrier.
- the next biopanning rounds were performed in the same manner as round 1 , except that: (i) input phage in the binding reaction were increased to 4.5x10 11 pfu, (ii) time of binding was reduced to 2hr in round 4, (iii) Tween-20 concentration in a washing buffer was increased to 0.2% in round 3 and 0.4% in round 4, (iv) eluted phage from last round 4 were not amplified, but rather served as a source of independent phage clones used for sequencing.
- TR-4, RhR-4, OG-4 and Flu-4 phage sets were used as a source of independent phage clones that were sequenced for further analysis.
- Phage single-stranded DNAs ss DNAs
- ds DNAs double-stranded DNAs
- Fluorette-coding portions of the DNA and adjacent DNA regions were sequenced with -96 gill sequencing primer CCCTCATAGTTAGCGTAACG (New England Biolabs) (SEQ ID NO: 115) using an Applied Biosystems 391 automated DNA sequencer.
- the sequences from the insert regions of the phage are grouped in Table 1. Two unique sequences were found that bound to the Texas Red conjugate beads, one for Rhodamine Red, seven for Oregon Green, and six for Fluorescein. Note that the Oregon Green set and the Fluorescein set shared two sequences that were identical at the nucleotide level as well as the amino acid sequence presented. These and other issues relevant to such observations are explored later.
- Phage selected against the Texas Red carrier gave rise to the sequences KHVQYWTQMFYS and DFLQWKLARQKP at a 5:1 ratio (Table 1).
- Biopanning with the phage display library against the Rhodamine Red carrier gave rise to a single phage clone, RhR401 , carrying the amino acid sequence IPHPPMYWTRVF.
- TR-4 and RhR-4 phage sets may be considered to be nearly "pure" phage clone populations by the fourth round of selection.
- TR401 and RhR401 phage were selected against the polymer linker moiety rather than a fluorophore dye moiety of the dye carriers.
- the TR-4 and RhR-4 phage were cross-bound to Rhodamine Red and Texas Red carriers, respectively. Cross-binding of each phage to the inappropriate dye carrier did not exceed the nonspecific phage background binding (data not shown).
- the TR401 and RhR401 fluorettes are specific by this comparison for their respective conjugated dyes, despite the similarity of the compound core ring structures. Second, they had affinity for the corresponding conjugated fluorophore dyes rather than only a polymer linker moiety of Texas Red and Rhodamine Red carriers or other chemical features of the carriers themselves.
- Oregon Green 514 is structurally related to Fluorescein, and is considered a Fluorescein pentafluoride (see Figure 1), independent selection of the same peptide fluorettes against Oregon Green 514 and Fluorescein carriers was predicted. The same fluorettes selected independently against these fluorophores possibly bind to similar domains of the Oregon Green 514 and Fluorescein dye molecules.
- the selected phage had been originally selected as being capable of binding fluorophore dyes that had been covalently linked to a polymer carrier.
- the nature of carrier-crosslinked fluorophores, while useful for initial selection of phage, is inappropriate to study affinity of the phage except in relative terms.
- Each bactenophage particle contains 5 copies of plll-fluorette fusion protein. Therefore phage binding is governed by avidity considerations.
- RhR401 , OG402, OG403 (1.3-1.8x10 phage particles; calculated from optical densities of the purified phage at 260 and 280nm) in TBS + 0.05% sodium azide buffer were separately mixed with an equal volume of 20 ⁇ M solution of the corresponding free dyes in the same buffer; mixtures were adjusted by Tween-20 to 0.1 % and incubated for 3hr.
- Phage-fluorophore dye complexes were precipitated three times by PEG-8000 in order to remove unbound dye and dissolved in 6.6 ⁇ l of TBS + 0.05% sodium azide buffer.
- phage-fluorophore dye complexes (1 ⁇ l of each) were spotted to nitrocellulose filter and filter was scanned on the Storm 840 scanner (Molecular
- the complexity of the phage display peptide library used for biopanning against the fluorophore dye carriers was much smaller, containing only 1.9x10 9 clones.
- the library represents a fraction of all possible 12-mer peptides that could have been searched for binding. We therefore sought to improve the present fluorettes.
- TR401-91CL CTCCCCTTCGGCCGAACCTCCACCAGAATAAAACATCTGCGTCCAATACTGCACATGCTTA GAGTGAGAATAG-AAAGGTACCACTCTCCC (SEQ ID NO:88);
- OG402-91CL CTCCCCTTCGGCCG CCTCCACCAAAATAATACTCCCACCACTCAAAATCATTCGGATAA
- GAGTGAGAATAGAAAGGTACCACTCTCCC (SEQ ID NO:90); OG403-91CL: CTCCCCTTCGGCCGAACCTCCACCCCAAGCAGTCCAATCCCAATAATAATCCCACCCATGA
- GAGTGAGAATAGAAAGGTACCACTCTCCC (SEQ ID NO:91 ).
- Nucleotides in a regular case shows no degeneracy; boldfaced nucleotide designates 91% of shown nucleotide and 3x3% of each of the other three nucleotides; boldfaced and underlined nucleotide designates 91 % of A or C and 9% of C or A, respectively.
- Ph.D.121 was a randomly picked phage clone from the Ph.D. -12 phage display peptide library) in a total volume 0.1ml. Ligations were electroporated into 0.5ml of TG-1 electrocompetent cells (Stratagene) according to manufacturer's protocol and phage library complexities were determined by immediate mixing of several 10-fold dilutions of transfected TG-1 cells with ER2537 cells and plating. Phage libraries were further amplified in 400ml of liquid LB media for 4hr at 37°C with vigorous shaking, concentrated by PEG (see above) and, finally, suspended in 0.5ml TBS + 0.05% sodium azide buffer.
- TG-1 electrocompetent cells (Stratagene) according to manufacturer's protocol and phage library complexities were determined by immediate mixing of several 10-fold dilutions of transfected TG-1 cells with ER2537 cells and plating. Phage libraries were further amplified in 400ml of liquid LB media for 4
- Titers of four resultant nonrandom combinatorial phage libraries were 0.2-4.0x10 13 pfu/ml.
- phage libraries were adjusted to 50% glycerol and stored at -20°C. Twelve independent phage clones from each TR401-91CL and RhR401-91CL libraries were sequenced in order to determine the average level of amino acid substitutions in the fluorette moiety.
- a key difference of the secondary biopanning versus the primary biopanning with the original phage library is the strict need to maximize selection against the originating, parental fluorette
- phage clones were isolated after three biopanning rounds with TR401-91CL, RhR401- 91 CL, OG403-91CL and OG402-91CL nonrandom combinatorial phage display peptide libraries (see text), b) ammo acid substitutions in mutant peptide fluorette vs the corresponding parent are shown, mutant peptide fluorette sequence is shown as many times as it was found (see phage clone frequency), dots designate the same ammo acid as that in the corresponding parent, dash in a second position of the FluS304 fluorette designates m- frame deletion, c) original parental clones and the parental clones carrying silent mutat ⁇ on(s) in peptide fluorette moiety
- PEG-purified phage (input 5x10 8 -2 5x10 10 pfu with 2 to 5-fold increments) were bound to the respective fluorophore dye carriers essentially in the same manner as described above for Texas Red-specific phage RhR401 and RhRS308, OG403 and OGS316, OG402 and FluS303 phage, were bound to the Rhodamine Red, Oregon Green 514 or Fluorescein carriers, respectively Following binding the beads were quickly washed twice by 0 25ml of TBS + 0 1 % Tween-20 and suspended in 10ml TBS 10 ⁇ l of suspension was mixed with " 2x10 8 log-phase ER2537 cells and incubated 1hr at 4°C with slight shaking to allow phage adsorption Several ten-fold dilutions of infected cells were mixed with nonmfected ER2537 cells and plated in standard plaque assay (Sambrook et al , supra) All binding experiments and titrations were accomplished in
- the TR401 peptide is the progenitor of the TRS311 peptide.
- the two substitutions H2P and S12T result not only in an increased binding, but also in an apparent differences in the excitation spectra elicited.
- PepTRS311 had a peak emission spectra shift.
- one or both of the two substitutions, H2P or S12T are critical for shifting the spectra of the emission profile.
- peptide names reflect the names of phage clones carrying respective fluorettes except Pep.
- Control see Tables 1 and 2
- first twenty amino acids of the peptides are the same as in the pill fusion protein of the corresponding phage clones except Pep.
- Control see Tables 1 and 2 and also New England Biolabs "Ph.D.-12 Phage Display Peptide Library Kit” manual
- amino acids 1-12 are the fluorette potion (double underlined)
- amino acids 13-20 are the distal pill fusion part (underlined).
- Amino acids 21-29 contain a small GGG spacer followed by His 6 tag (shown in regular case).
- SEQ ID NOS:41-48) c) specific for both Oregon Green 514 and Fluorescein (see Table 1).
- Constrained Texas Red-Binding Peptides were identified via five rounds of biopanning of a mixture of two constrained phage display libraries against a polymer carrier with covalently bound Texas Red Two libraries contained SKVILFE-flanked nine or thirteen ammo acid variable region in the N-terminal part of M13 bactenophage pill protein The structure of the libraries were as follows
- GGGSKVILFEGPAG (X) 9 or 13 GAPGSKVILFEGGPG (SEQ ID NO 93)- (pill protein)
- SKVILFE-dime ⁇ zers are underlined Flexible linkers or spacers GGG, GPAG ( SEQ ID NO 94), GAPG (SEQ ID NO 95) and GGPG (SEQ ID NO 96) are double underlined X represents any ammo acid
- the flexible linker or spacer GPAG is encoded by a nucleotide sequence containing Fsel restriction endonuclease site
- the flexible linker or spacer GAPG is encoded by a nucleotide sequence containing Ascl restriction endonuclease site
- Fsel and Ascl restriction enzymes are rare eight-cutters
- SEQ.ID NO:103 Consensus motifs can be observed within these peptides (e.g., RXXWEP (SEQ ID NO:104), WEP and TW; see Table 5) that suggests structural features common to the peptides that allow for efficient binding. Interestingly, no said constrained peptide has a significant homology with linear Texas Red-binding peptides.
- Binding affinity of phage clones revealed the most avid binders, TRP512 phage and TRP501 phage, with equal to 25 pM and 80 pM, respectively. Other five phage clones were much less avid with K,, ⁇ 5 nM (see Table 5).
- phage clones were isolated after five biopanning rounds with a mixture of combinatorial P71 R4-CL-9 & P71 R4-CI-13 phage display peptide libraries b) -1 (D,E) or +1 (K,R) c) number of hydrophobic amino acids (A,V,L,I,W,Y,F) per total number of fluorette amino acids * ) phage clone is represented in the corresponding group at least twice
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU11202/00A AU1120200A (en) | 1998-10-16 | 1999-10-15 | Fluorescent dye binding peptides |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10446598P | 1998-10-16 | 1998-10-16 | |
| US60/104,465 | 1998-10-16 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO2000023463A2 true WO2000023463A2 (en) | 2000-04-27 |
| WO2000023463A3 WO2000023463A3 (en) | 2000-08-17 |
| WO2000023463A9 WO2000023463A9 (en) | 2001-07-05 |
Family
ID=22300633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1999/024266 Ceased WO2000023463A2 (en) | 1998-10-16 | 1999-10-15 | Fluorescent dye binding peptides |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU1120200A (en) |
| WO (1) | WO2000023463A2 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2871464A1 (en) * | 2004-06-15 | 2005-12-16 | Centre Nat Rech Scient | COLLECTIONS OF TRACEABLE COMPOUNDS AND USES THEREOF |
| WO2009005579A1 (en) * | 2007-06-14 | 2009-01-08 | The General Hospital Corporation | High affinity fluorochrome binding peptides |
| EP1910406A4 (en) * | 2005-08-01 | 2010-12-01 | Du Pont | Coloring compositions with peptide-based dispersants and binders |
| US20110033866A1 (en) * | 2007-09-14 | 2011-02-10 | Biosentinel, Llc | Resonance Energy Transfer Assay with Cleavage Sequence and Spacer |
-
1999
- 1999-10-15 AU AU11202/00A patent/AU1120200A/en not_active Abandoned
- 1999-10-15 WO PCT/US1999/024266 patent/WO2000023463A2/en not_active Ceased
Non-Patent Citations (1)
| Title |
|---|
| LEFEVRE C ET AL: "TEXAS RED-X AND RHODAMINE RED-X, NEW DERIVATIVES OF SULFORHODAMINE 101 AND LISSAMINE RHODAMINE B WITH IMPROVED LABELING AND FLUORESCENCE PROPERTIES" BIOCONJUGATE CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY, WASHINGTON, vol. 7, no. 4, 1996, pages 482-489, XP000882552 ISSN: 1043-1802 * |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2871464A1 (en) * | 2004-06-15 | 2005-12-16 | Centre Nat Rech Scient | COLLECTIONS OF TRACEABLE COMPOUNDS AND USES THEREOF |
| WO2006003330A3 (en) * | 2004-06-15 | 2006-10-26 | Centre Nat Rech Scient | Collections of traceable compounds and uses thereof |
| EP1910406A4 (en) * | 2005-08-01 | 2010-12-01 | Du Pont | Coloring compositions with peptide-based dispersants and binders |
| WO2009005579A1 (en) * | 2007-06-14 | 2009-01-08 | The General Hospital Corporation | High affinity fluorochrome binding peptides |
| US20110033866A1 (en) * | 2007-09-14 | 2011-02-10 | Biosentinel, Llc | Resonance Energy Transfer Assay with Cleavage Sequence and Spacer |
| US20130095513A1 (en) * | 2007-09-14 | 2013-04-18 | Biosentinel, Inc. | Resonance Energy Transfer Assay with Cleavage Sequence and Spacer |
| US8969016B2 (en) * | 2007-09-14 | 2015-03-03 | Biomadison, Inc. | Resonance energy transfer assay with cleavage sequence and spacer |
| US20150176051A1 (en) * | 2007-09-14 | 2015-06-25 | Biomadison, Llp | Resonance Energy Transfer Assay with Cleavage Sequence and Spacer |
| US9249451B2 (en) * | 2007-09-14 | 2016-02-02 | Biomadison, Inc. | Resonance energy transfer assay with cleavage sequence and spacer |
| US9303284B2 (en) * | 2007-09-14 | 2016-04-05 | Biomadison, Inc. | Resonance energy transfer assay with cleavage sequence and spacer |
| US9677113B2 (en) | 2007-09-14 | 2017-06-13 | Biomadison, Inc. | Resonance energy transfer assay with cleavage sequence and spacer |
| US10526637B2 (en) | 2007-09-14 | 2020-01-07 | Biomadison, Inc. | Compositions and methods for improved neurotoxin assays |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000023463A3 (en) | 2000-08-17 |
| WO2000023463A9 (en) | 2001-07-05 |
| AU1120200A (en) | 2000-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12275760B2 (en) | Amino acid-specific binder and selectively identifying an amino acid | |
| AU781478B2 (en) | Methods and compositions for the construction and use of fusion libraries | |
| AU2007200355B2 (en) | Yeast cell surface display of proteins and uses thereof | |
| US20250042947A1 (en) | Peptide library and use thereof | |
| US6747135B1 (en) | Fluorescent dye binding peptides | |
| WO2014205518A1 (en) | Method of monitoring cellular trafficking of peptides | |
| US20030049647A1 (en) | Use of nucleic acid libraries to create toxicological profiles | |
| US20050277116A1 (en) | Compositions and methods for the identification of protein interactions in vertebrate cells | |
| EP3704244B1 (en) | Vector construct | |
| WO2000023463A2 (en) | Fluorescent dye binding peptides | |
| US9400249B2 (en) | Detection of biopolymer interactions, cancer cells, and pathogens using split-supercharged GFP | |
| JP2006506950A (en) | Two green fluorescent protein fragments and their use in a method for detecting protein-protein interactions | |
| CA2419908A1 (en) | High throughput method and kit | |
| Tos | Team: LMU-TUM Munich/Localization | |
| Tos | Team: LMU-TUM Munich/project | |
| JP2004024078A (en) | Random oligonuceleotide library and method for detecting protein interaction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ENP | Entry into the national phase in: |
Ref country code: AU Ref document number: 2000 11202 Kind code of ref document: A Format of ref document f/p: F |
|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| AK | Designated states |
Kind code of ref document: C2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| COP | Corrected version of pamphlet |
Free format text: PAGES 1/8-8/8, DRAWINGS, REPLACED BY NEW PAGES 1/7-7/7; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 122 | Ep: pct application non-entry in european phase |